Biorepository to Support Research in Kidney Diseases
Launched by YALE UNIVERSITY · Apr 9, 2020
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
A biorepository of human samples to support research to advance understanding of human kidney diseases will be created. Clinically, kidney diseases are detected by blood and urine laboratory tests. However, the underlying cause of kidney disease is often not clear on blood and urine tests. In such cases, a clinician may choose to perform a kidney biopsy to establish the diagnosis. Patients who are scheduled to undergo a kidney biopsy will be invited to participate in this proposed study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients scheduled to undergo a clinically indicated kidney biopsy
- • English or Spanish speaking
- Exclusion Criteria:
- • Under 18 years or age
- • Known pregnancy
- • Additional vulnerable individuals (incarcerated, institutionalized, or otherwise unable to participate in the study)
- • Inability to provide informed consent
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
New Haven, Connecticut, United States
Patients applied
Trial Officials
Dennis G Moledina, MD
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials